Neos Therapeutics logo
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
March 12, 2021 09:04 ET | Neos Therapeutics, Inc.
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – –...
Neos Therapeutics logo
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience
March 10, 2021 16:01 ET | Neos Therapeutics, Inc.
– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – –...
Neos Therapeutics logo
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021
February 10, 2021 08:00 ET | Neos Therapeutics, Inc.
– Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE,...
Neos Therapeutics logo
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference
January 04, 2021 16:01 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics logo
Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical Company
December 10, 2020 08:00 ET | Neos Therapeutics, Inc.; Aytu BioScience
Merger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022  Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s...
Neos Therapeutics logo
Neos Therapeutics Reports Third Quarter 2020 Financial Results
November 09, 2020 07:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics logo
Neos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020
November 02, 2020 08:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics logo
Neos Therapeutics to Present at Cantor Virtual Global Healthcare Conference
September 09, 2020 08:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics logo
Neos Therapeutics Reports Second Quarter 2020 Financial Results
August 10, 2020 07:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
Neos Therapeutics logo
Neos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020
August 03, 2020 08:00 ET | Neos Therapeutics, Inc.
DALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...